Tempero M A, Behrman S, Ben-Josef E, et al. Pancreatic adenocarcinoma: Clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2005,3(5):598.
[2]
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer:a randomized controlled trial[J]. JAMA, 2007,297(3):267.
[3]
Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial[J]. Lancet Oncol, 2005,6(6):369.
[4]
Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial[J]. J Clin Oncol, 2005,23(15):3509.
[5]
Rocha Lima C M, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer[J]. J Clin Oncol, 2002,20(5):1182.
[6]
Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer[J]. J Clin Oncol, 2006,24(24):3946.
[7]
Burtness B, Thomas L, Sipples R, et al. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer[J]. Cancer J, 2007,13(4):257.
[8]
Su Y T, Chang H L, Shyue S K, et al. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway[J]. Biochem Pharmacol, 2005,70(2):229.
[9]
Lin S Y, Lai W W, Ho C C, et al. Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways[J]. Anticancer Res, 2009,29(1):327.
[10]
Guo Q, Chen Y, Zhang B, et al. Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition[J]. Biochem Pharmacol, 2009,77(11):1674.
[11]
Cha T L, Qiu L, Chen C T, et al. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth[J]. Cancer Res, 2005,65(6):2287.
[12]
Tang Z Y, Wu Y L, Gao S L, et al. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells[J]. J Surg Res, 2008,145(1):111.
Kullmann F, Hollerbach S, Dollinger M M, et al. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: A multicentre phase II study[J]. Br J Cancer, 2009,100(7):1032.
[16]
Cai J, Razzak A, Hering J, et al. Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro[J]. J Parenter Enteral Nutr,2008,32(2):190.
[17]
Zhang L, Hung M C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin[J]. Oncogene, 1996,12(3):571.
[18]
Zhang L, Lau Y K, Xia W, et al. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel[J]. Clin Cancer Res, 1999,5(2):343.
[19]
Lai G H, Zhang Z, Sirica A E. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3[J]. Mol Cancer Ther, 2003,2(3):265.
[20]
Bold R J, Chandra J, McConkey D J. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content[J]. Ann Surg Oncol, 1999,6(3):279.
[21]
Xu Z W, Friess H, Buchler M W, et al. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents[J]. Cancer Chemother Pharmacol, 2002,49(6):504.
[22]
van Beek-Harmsen B J, van der Laarse W J. Immunohistochemical determination of cytosolic cytochrome C concentration in cardiomyocytes[J]. J Histochem Cytochem, 2005,53(7):803.
